Fracture risk tool useful in women with breast cancer initiating aromatase inhibitor therapy

The FRAX® tool takes into account certain factors to determine the risk of bone fracture in the general population. In a Journal of Bone and Mineral Research study, the tool was effective at determining fracture risk for women with breast cancer who were treated with aromatase inhibitors, which cause accelerated bone loss, when combined with bone mineral density measurements.
Source: EurekaAlert,